Analyte and PK parameter | Adjusted geometric mean (n) with the following treatment: | Test treatment/reference treatment ratio (90% CI) | |
---|---|---|---|

Test (DTG-RPV FDC tablet) | Reference (DTG and RPV separate tablets) | ||

DTG | |||

AUC_{0–∞} (μg · h/ml) | 64.968 (113) | 62.655 (113) | 1.037 (1.010, 1.064) |

AUC_{0–} (μg · h/ml)_{t} | 63.583 (113) | 61.265 (113) | 1.038 (1.011, 1.066) |

C_{max} (μg/ml) | 3.646 (113) | 3.474 (113) | 1.050 (1.022, 1.078) |

C_{24}^{a} | 1.001 (112) | 0.958 (112) | 1.044 (1.012, 1.077) |

RPV | |||

AUC_{0–∞} (μg · h/ml)^{b} | 3.248 (112) | 2.933 (112) | 1.108 (1.045, 1.174) |

AUC_{0–} (μg · h/ml)_{t} | 3.062 (113) | 2.767 (113) | 1.107 (1.042, 1.176) |

C_{max} (μg/ml) | 0.093 (113) | 0.083 (113) | 1.124 (1.047, 1.207) |

C_{24} | 0.031 (113) | 0.028 (113) | 1.101 (1.034, 1.173) |

↵a Paired data only; 1 participant was excluded because of a missing result in period 2.

↵b Paired data only; 1 participant was excluded because in period 1 the percentage of AUC

_{0–∞}that was extrapolated was >20%,*R*^{2}was <0.85 in estimation of the terminal-phase rate constant, and the range of time over which the half-life (*t*_{1/2}) was calculated was <2 ×*t*_{1/2}.↵c AUC, area under the concentration-time curve; AUC

_{0–}, AUC from 0 h to the last quantifiable measurement; AUC_{t}_{0–∞}, AUC from 0 h to infinity;*C*_{24}, plasma concentration at 24 h postdose; CI, confidence interval;*C*_{max}, maximum concentration of drug in plasma; DTG, dolutegravir; FDC, fixed-dose combination; RPV, rilpivirine;*n*, number of participants.